Table 1.
Author and Reference | Study type | Duration of treatment | Patients | Age | Pain assessment | Outcome | Adverse reaction |
---|---|---|---|---|---|---|---|
Loch (29) | Cohort | 3 Months | 1634 | 36 (9) | Questionnaire | 85% reduction | 1% |
Halaska (31) | RCT with placebo | 3 Months | VAC 48 Placebo 49 | 36 (6) | VAS | 54% reduction | 5/48 4/49 |
Atmaca (32) | RCT with Fluoxetine | 2 Months | VAC 20 Fluoxetine 21 | 33 (11) | HAM-D DSR CGI-SI | 50% reduction | |
Berger (30) | Cohort | 3 Months | 50 | 31 (8) | VAS | 45% reduction | 20/50 |
Schellenberg (33) | RCT with placebo | 3 Months | VAC 86 Placebo 84 | 36 | DMS-III-R | 52% reduction | 4/86 3/84 |